Compare Sana Biotechnology Inc (SANA) vs Sibanye Stillwater Ltd (SBSW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Sibanye Stillwater Ltd — how do they compare? Sana Biotechnology Inc trades at $3.17 (market cap $1.03B), while Sibanye Stillwater Ltd trades at $13.14 (market cap $9.35B). The key difference: Sibanye Stillwater Ltd is far larger — about 9.1× Sana Biotechnology Inc's market cap, and Sibanye Stillwater Ltd pays a 6.27% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | SBSW | |
|---|---|---|
Market Cap | $1.03B | $9.35B |
Sector | Health | Basic Materials |
52-Week High | $5.92 | $21.12 |
52-Week Low | $2.68 | $8.00 |
Enterprise Value | $946.04M | $10.29B |
Dividend Yield | — | 6.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
SBSW trades at $12.90, up 0.86% today, with a bullish technical signal from moving averages and ADX indicators. Recent Q2 2026 earnings beat expectations with EPS of $1.34 versus $1.26, and the company reported a strong turnaround in operating cash flow to $21.41 billion in 2025. Valuation ratios appear attractive with a P/E of 10.2 and EV/EBITDA of 5.2, while analyst consensus is a Buy with a $14.00 price target.
The outlook is positive due to robust earnings performance and improving cash flows, but risks include volatile commodity prices and high debt levels. Investment opportunity lies in potential upside to the consensus target, supported by operational momentum and disciplined capital allocation plans highlighted in recent news.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →
